Verano Subsidiary Declares Flagship Pharmacy Opening In Pittsburgh With Western … Information

The freestanding pharmacy is located in The Mall at Robinson, a busy retail and hospitality community, near the intersection of I-376 and Lincoln Highway. It is also the first pharmacy in western Pennsylvania with a four-lane drive-through that offers a uniquely comfortable patient experience. This is the 80th active pharmacy nationwide for the company and its subsidiaries. Verano expects the opening of a total of seven pharmacies in its active presence in 11 states, including new locations in Florida and Nevada, as well as two additional storefronts in Pennsylvania by the subsidiary Agronomed Biologics by the end of 2021. This is the second of six licensed clinical registrant pharmacies opened in Pennsylvania by Verano subsidiary Agronomed Biologics, and the company’s twelfth affiliated, active pharmacy in the state.

CHICAGO, July 30, 2021 (GLOBE NEWSWIRE) – Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of. announced a new storefront, the Healing Research Center in Pittsburgh. As part of the state’s Chapter 20 Clinical Registrant Program, the pharmacy, in partnership with Drexel University’s Medical Cannabis Research Center, will conduct ongoing research into medical cannabis and its effects on various diseases covered by the Pennsylvania program. The Pittsburgh Healing Research Center is the first medical cannabis dispensary in western Pennsylvania to have a drive-through platform for its patients and is located near the interstate exits of I-79 and I-376 on Robinson Center Drive That typically involves combined traffic of approximately 200,000 cars per day, according to the Pennsylvania Department of Transportation.

“With this flagship pharmacy and unique partnership with Drexel, we have the opportunity to enhance the medical cannabis program in Pennsylvania, a core market for Verano and one of the largest in the country,” said George Archos, Founder and CEO of Verano. “Research supports our vision to continuously improve patient care and experience. This initiative brings together some of the brightest talent in our industry with one of the best medical institutions in Pennsylvania to work together to improve the medical cannabis landscape for generations of patients to come. “

The Verano subsidiary Agronomed Biologics is allowed to open a facility for the cultivation and production of medical cannabis as well as six pharmacies in Pennsylvania as part of its approval as a clinical registrant. The Healing Research Center is located at 6300 Robinson Center Drive in Pittsburgh. The pharmacy is scheduled to open on Friday, July 30th, at 10:00 a.m. local time. The regular business hours are Monday to Friday 10:00 a.m. to 8:00 p.m., Saturday 10:00 a.m. to 6:00 p.m. and Sunday 10:00 a.m. to 4:00 p.m.

About Verano

Verano is a leading, vertically integrated, multi-state cannabis operator in the United States dedicated to continuously improving community wellbeing by providing responsible access to regulated cannabis products. With a mission to meet vital health and wellness needs, Verano produces a full line of innovative premium cannabis products sold under its proven portfolio of consumer brands including Verano ™, Avexia ™, Encore ™ and MÜV ™. Verano’s portfolio spans 14 states with active operations in 11, including 10 manufacturing facilities with approximately 832,000 square feet of acreage (including a 26,000 square foot facility in Massachusetts nearing completion). Verano designs, builds and operates pharmacies under retail brands such as Zen Leaf ™ and MÜV ™, providing a superior cannabis shopping experience in both the medical and adult markets. Find out more at www.verano.com.

Forward-Looking Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities laws and may contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and Forward-looking statements are not representative of historical facts or information or current conditions, but instead only represent the company’s beliefs about future events, plans or goals, many of which are inherently uncertain and beyond the control of the company. In general, such forward-looking information or forward-looking statements may be identified by the use of forward-looking terminology such as “plans,” “expected,” “expected,” “is expected,” “budget,” “planned,” “estimates,” “forecasts “,” intends “,” anticipates “or” does not expect “or” believes “, or variations of such words and expressions, or may contain statements that” might “,” might “,” would “,” could be “or“ is taken, ”“ continues, ”“ will occur, ”or“ will be achieved. ”The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements or information relating to the company’s position on the Market, the planned completion or planned expansion of the operating facilities, the company’s cultivation capacities, the consolidation of the company’s presence in core markets en, the opportunity for substantial organic expansion, the provision of shareholder value, and the ability to maintain industry-leading margins and strengthen leadership.

Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties and other factors that could cause actual events, results, performance or achievements of the company to be materially different from future events, results, performance, and achievements by forward-looking Information and statements expressed or implied herein, including, but not limited to, the risk factors discussed in the company’s records on SEDAR at www.sedar.com.

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release and the company undertakes no obligation to update any forward-looking information or forward-looking statements contained or referenced herein, except in accordance with the applicable securities laws. All of the following written and oral forward-looking information and statements that can be attributed to the company or persons acting on its behalf are expressly restricted in their entirety by this release with regard to forward-looking information and statements.

# # #

Contacts:

Investors Verano Aaron Miles Chief Investment Officer aaron@verano.holdings

Media Verano David Spreckman Vice President, Marketing & Communications david@verano.holdings 312-819-4852

Sard Verbinnen & Co. Gabriella Coffey / Ryan McDougald Verano-SVC@sardverb.com

Copyright 2021 GlobeNewswire, Inc.

Comments are closed.